RVO biomarkers can be established using an AI that draws out from intravenous fluorescein angiography and baseline characteristics.

KOCHI: 68-year-old Thankamma (name changed) from Ernakulam has been a diabetic patient for 15 years. As she did not manage ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Reports Q3 revenue $3.72B, consensus $3.67B. “Regeneron (REGN) had a strong third quarter marked by 11% revenue growth. We continued to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2024 and provided a business update. "Regeneron had a strong third quarter marked by 11% ...

Retinal Vein Occlusion Market New report uncovers key trends and growth opportunities in the Retinal Vein Occlusion market, focusing on i ...

Improved diagnosis and treatment for eye diseases affecting the sight of millions across the globe has taken a major step ...

High cholesterol, often a result of an unhealthy lifestyle, can heighten the risk of serious health conditions such as heart ...

Jonathan Brugger, MD, shared insights on the correlation of central retinal vein occlusions, or branch retinal vein ...